$ODYY
Odyssey Group of Companies Stock $odyy

$odyy Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-K Financial Statement

#000168316824007967 Filed on November 13, 2024

Income Statement

Concept	2024 Q4	2024
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development		$0.00
YoY Change		-100.0%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses		$0.00
YoY Change		-100.0%
Operating Profit		$14.26M
YoY Change		-368.37%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net		$9.265K
YoY Change		-16.82%
Pretax Income
YoY Change
Income Tax		$0.00
% Of Pretax Income
Net Earnings		-$842.3K
YoY Change		-85.77%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.01
Diluted Earnings Per Share		-$0.01
COMMON SHARES
Basic Shares Outstanding	96.71M shares	97.06M shares
Diluted Shares Outstanding		97.06M shares

Balance Sheet

Concept	2024 Q4	2024 Q3	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents		$2.379K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables		$22.63K
Total Short-Term Assets		$56.94K
YoY Change		-85.97%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets		$529.2K
YoY Change		960.42%
TOTAL ASSETS
Total Short-Term Assets		$56.94K
Total Long-Term Assets		$529.2K
Total Assets		$586.1K
YoY Change		28.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$1.276M
YoY Change		-29.02%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$5.920M
YoY Change		-10.46%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities		$5.920M
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings		-$61.00M
YoY Change		1.51%
Common Stock		$96.71K
YoY Change		22.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		-$5.334M
YoY Change
Total Liabilities & Shareholders Equity		$586.1K
YoY Change		28.6%

Cashflow Statement

Concept	2024 Q4	2024 Q3	2024
OPERATING ACTIVITIES
Net Income			-$842.3K
YoY Change			-85.77%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities			-$1.215M
YoY Change			-17.6%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities			$1.000M
YoY Change			-10039.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities			$180.7K
YoY Change			-87.53%
NET CHANGE
Cash From Operating Activities			-$1.215M
Cash From Investing Activities			$1.000M
Cash From Financing Activities			$180.7K
Net Change In Cash			-$34.49K
YoY Change			-3.32%
FREE CASH FLOW
Cash From Operating Activities			-$1.215M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	0	usd
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96709763	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96709763	shares
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	2820311	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-5314015	usd
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001626644
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	ODYY	Unrealized Gain Loss On Investments1 UnrealizedGainLossOnInvestments1		usd
CY2024	ODYY	Warrants Exercised In Connection With Debt Financing WarrantsExercisedInConnectionWithDebtFinancing		usd
CY2024	ODYY	Return Of Shares To Treasury ReturnOfSharesToTreasury		usd
CY2024	us-gaap	Dividends Dividends		usd
CY2023	ODYY	Unrealized Gain Loss On Investments1 UnrealizedGainLossOnInvestments1		usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-07-31
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--07-31
CY2024	dei	Entity File Number EntityFileNumber	000-56196
CY2024	dei	Entity Registrant Name EntityRegistrantName	ODYSSEY HEALTH, INC.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1022125
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	2300 West Sahara Avenue
CY2024	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 800 - #4012
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Las Vegas
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	89102
CY2024	dei	City Area Code CityAreaCode	702
CY2024	dei	Local Phone Number LocalPhoneNumber	780-6559
CY2024	dei	Security12g Title Security12gTitle	Common Stock ($0.001 par value)
CY2024	dei	Trading Symbol TradingSymbol	ODYY
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Public Float EntityPublicFloat	6881266	usd
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	96709763	shares
CY2024	dei	Auditor Firm AuditorFirmId	76
CY2024	dei	Auditor Name AuditorName	Turner, Stone & Company, L.L.P.
CY2024	dei	Auditor Location AuditorLocation	Dallas, Texas
CY2024Q3	us-gaap	Cash Cash	2379	usd
CY2023Q3	us-gaap	Cash Cash	36865	usd
CY2024Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	22625	usd
CY2023Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	276566	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	31939	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	92457	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	56943	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	405888	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	49905	usd
CY2024Q3	us-gaap	Investments Investments	529203	usd
CY2023Q3	us-gaap	Investments Investments	0	usd
CY2024Q3	us-gaap	Assets Assets	586146	usd
CY2023Q3	us-gaap	Assets Assets	455793	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1275996	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1797656	usd
CY2024Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1648586	usd
CY2023Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1402348	usd
CY2024Q3	us-gaap	Interest Payable Current InterestPayableCurrent	223754	usd
CY2023Q3	us-gaap	Interest Payable Current InterestPayableCurrent	142032	usd
CY2024Q3	us-gaap	Assets Sold Under Agreements To Repurchase Repurchase Liability AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability	1125026	usd
CY2023Q3	us-gaap	Assets Sold Under Agreements To Repurchase Repurchase Liability AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability	1125026	usd
CY2024Q3	ODYY	Notes Payable Related Parties Classified Current1 NotesPayableRelatedPartiesClassifiedCurrent1	100000	usd
CY2023Q3	ODYY	Notes Payable Related Parties Classified Current1 NotesPayableRelatedPartiesClassifiedCurrent1	125000	usd
CY2024Q3	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	38134	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	280340	usd
CY2024Q3	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	1546533	usd
CY2023Q3	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	2019660	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5919895	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6611722	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	79067879	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	79067879	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	96710	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	79068	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	55572687	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	53862378	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61003146	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-60097375	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-5333749	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-6155929	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	586146	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	455793	usd
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	170000	usd
CY2024	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	55166	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	201329	usd
CY2024	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	577805	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1506641	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2122375	usd
CY2024	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	16400687	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	14261075	usd
CY2024	us-gaap	Asset Impairment Charges AssetImpairmentCharges	12955437	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	-0	usd
CY2024	ODYY	Unrealized Gain Loss On Investments1 UnrealizedGainLossOnInvestments1	-1638743	usd
CY2024	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	518476	usd
CY2023	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	614083	usd
CY2024	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9265	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8677	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-842316	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5919421	usd
CY2024	us-gaap	Dividends Common Stock DividendsCommonStock	63455	usd
CY2023	us-gaap	Dividends Common Stock DividendsCommonStock	-0	usd
CY2024	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-905771	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5919421	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97064040	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82677354	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97064040	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82677354	shares
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-6155929	usd
CY2024	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	577805	usd
CY2024	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	55620	usd
CY2024	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1002623	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	28448	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-842316	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-5333749	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-4643617	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2820311	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	580220	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	478000	usd
CY2023	ODYY	Common Stock Issued In Debt Financing CommonStockIssuedInDebtFinancing	13443	usd
CY2023	ODYY	Common Stock Issued In Option Purchase Agreement CommonStockIssuedInOptionPurchaseAgreement	170000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	345135	usd
CY2023	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5919421	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-6155929	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-842316	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-5919421	usd
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1538	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3416	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	577805	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	2820311	usd
CY2024	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	16400687	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-0	usd
CY2024	us-gaap	Asset Impairment Charges AssetImpairmentCharges	12955437	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2024	ODYY	Unrealized Gain Loss On Investments1 UnrealizedGainLossOnInvestments1	-1638743	usd
CY2024	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	8750	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1750	usd
CY2024	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	330654	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	532434	usd
CY2024	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	0	usd
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	170000	usd
CY2024	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-60518	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	5048	usd
CY2024	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-253941	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-89908	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-195988	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	248087	usd
CY2024	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	246238	usd
CY2023	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	505648	usd
CY2024	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	150157	usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	78219	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1215210	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1474696	usd
CY2024	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	1000000	usd
CY2023	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	usd
CY2024	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	10061	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1000000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10061	usd
CY2024	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	400000	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	903868	usd
CY2024	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	274896	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	35000	usd
CY2024	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	55620	usd
CY2023	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	580220	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	180724	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1449088	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-34486	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-35669	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36865	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72534	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2379	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36865	usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet	37376	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	3431	usd
CY2024	ODYY	Common Stock Issued To Settle Notes Payable CommonStockIssuedToSettleNotesPayable	925437	usd
CY2023	ODYY	Common Stock Issued To Settle Notes Payable CommonStockIssuedToSettleNotesPayable	478000	usd
CY2024	ODYY	Accrued Interest Paid With Common Stock AccruedInterestPaidWithCommonStock	68435	usd
CY2023	ODYY	Accrued Interest Paid With Common Stock AccruedInterestPaidWithCommonStock	0	usd
CY2024	ODYY	Increase In Fees Related To Extension Of Lgh Debt Maturity Date Recorded As Additional Principal IncreaseInFeesRelatedToExtensionOfLghDebtMaturityDateRecordedAsAdditionalPrincipal	60000	usd
CY2023	ODYY	Increase In Fees Related To Extension Of Lgh Debt Maturity Date Recorded As Additional Principal IncreaseInFeesRelatedToExtensionOfLghDebtMaturityDateRecordedAsAdditionalPrincipal	0	usd
CY2024	ODYY	Warrants Issued In Exchange For Debt Financing Fees WarrantsIssuedInExchangeForDebtFinancingFees	28448	usd
CY2023	ODYY	Warrants Issued In Exchange For Debt Financing Fees WarrantsIssuedInExchangeForDebtFinancingFees	345135	usd
CY2024	ODYY	Shares Returned To Treasury SharesReturnedToTreasury	100	usd
CY2023	ODYY	Shares Returned To Treasury SharesReturnedToTreasury	8800	usd
CY2024	ODYY	Deemed Dividend Non Cash DeemedDividendNonCash	63455	usd
CY2023	ODYY	Deemed Dividend Non Cash DeemedDividendNonCash	0	usd
CY2024	ODYY	Original Issue Discount On Debt OriginalIssueDiscountOnDebt	0	usd
CY2023	ODYY	Original Issue Discount On Debt OriginalIssueDiscountOnDebt	98048	usd
CY2024	ODYY	Stock Issued In Exchange For Closing Costs StockIssuedInExchangeForClosingCosts	0	usd
CY2023	ODYY	Stock Issued In Exchange For Closing Costs StockIssuedInExchangeForClosingCosts	13443	usd
CY2024	ODYY	Accounts Payable Assumed By Oragenics AccountsPayableAssumedByOragenics	325672	usd
CY2023	ODYY	Accounts Payable Assumed By Oragenics AccountsPayableAssumedByOragenics	0	usd
CY2024	ODYY	Increase In Principal Of Notes Payable IncreaseInPrincipalOfNotesPayable	0	usd
CY2023	ODYY	Increase In Principal Of Notes Payable IncreaseInPrincipalOfNotesPayable	406132	usd
CY2024	ODYY	Shares Issued For Exercised Warrants SharesIssuedForExercisedWarrants	3537	usd
CY2023	ODYY	Shares Issued For Exercised Warrants SharesIssuedForExercisedWarrants	0	usd
CY2024	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80A_eus-gaap--NatureOfOperations_zY7UqPFkhxG6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 1. <span id="xdx_828_z29jmReJvFde">Nature of Operations and Going Concern</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our corporate mission is to create or acquire distinct assets, intellectual property, and technologies with an emphasis on acquisition targets that have clinical utility and will generate positive cash flow. Our business model is to develop or acquire medical related products, engage third parties to manufacture such products and then distribute the products through various distribution channels, including third parties. We have three different life saving technologies; the CardioMap® heart monitoring and screening device, the Save a Life choking rescue device and a 50% ownership in unique neurosteroid drug compound intended to treat rare brain disorders.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We intend to acquire other technologies and assets and plan to be a trans-disciplinary product development company involved in the discovery, development and commercialization of products and technologies that may be applied over various medical markets. We plan to license, improve and/or develop our products and identify and select distribution channels. We intend to establish agreements with distributors to get products to market quickly as well as to undertake and engage in our own direct marketing efforts. We will determine the most effective method of distribution for each unique product that we include in our portfolio. We will engage third-party research and development firms who specialize in the creation of our products to assist us in the development of our own products and we will apply for trademarks and patents once we have developed proprietary products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are not currently selling or marketing any products, as our products are in development and Food and Drug Administration (“FDA”) clearance or approval to market our products will be required to sell in the United States. In addition, it would require additional European union or country specific clearance or approvals to sell internationally.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We did not recognize any revenues for the years ended July 31, 2024 (“fiscal 2024”) or 2023 (“fiscal 2023”) and we had an accumulated deficit of $<span id="xdx_907_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20240731_z6Llvjk37Aef">61,003,146</span> as of July 31, 2024. For the foreseeable future, we expect to experience continuing operating losses and negative cash flows from operations. As of July 31, 2024, we had current liabilities of $<span id="xdx_909_eus-gaap--LiabilitiesCurrent_iI_c20240731_zeAnm5ciJah9">5,919,895</span>, current assets of $<span id="xdx_90D_eus-gaap--AssetsCurrent_iI_c20240731_z5KaFGltYhh3">56,943</span>, and a working capital deficit of $<span id="xdx_900_ecustom--WorkingCapital_iNI_di_c20240731_zHeoNH0drA2a" title="Working capital deficit">5,862,952</span>. Negative working capital at July 31, 2024 did not provide enough working capital to meet our current operating expenses through the first quarter of fiscal 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The operating deficit and negative working capital at July 31, 2024 indicate substantial doubt about our ability to continue as a going concern. Our continued existence depends on the success of our efforts to raise additional capital necessary to meet our obligations as they come due and to obtain sufficient capital to execute our business plan. We may obtain capital primarily through issuances of debt or equity or entering into collaborative arrangements with corporate partners. There can be no assurance that we will be successful in completing additional financing or collaboration transactions or, if financing is available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, we may be required to scale down or perhaps even cease operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The issuance of additional equity securities could result in a significant dilution in the equity interests of our current stockholders. Obtaining commercial loans, assuming those loans would be available, would increase our liabilities and future cash commitments. Our financial statements do not include adjustments that might result from the outcome of this uncertainty.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are continually adjusting our business plan to reflect our current liquidity expectations. If we are unable to raise additional capital, secure additional debt financing, secure additional equity financing, secure a strategic partner, reduce our operating expenditures, or seek bankruptcy protection, we will adjust our business plan. Given our recurring losses, negative cash flow, and accumulated deficit, there is substantial doubt about our ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61003146	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5919895	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	56943	usd
CY2024Q3	ODYY	Working Capital WorkingCapital	-5862952	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zNe0jbew6VX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zVpsO2kuEovl">Use of estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) generally requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2024	ODYY	Research And Development Expense Offset ResearchAndDevelopmentExpenseOffset	53578	usd
CY2023	ODYY	Research And Development Expense Offset ResearchAndDevelopmentExpenseOffset	261238	usd
CY2024	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1538	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3416	usd
CY2024Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1684667	usd
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2425000	usd
CY2024Q3	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	1684667	usd
CY2023Q3	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	2425000	usd
CY2024Q3	us-gaap	Notes Payable NotesPayable	1684667	usd
CY2023Q3	us-gaap	Notes Payable NotesPayable	2425000	usd
CY2024Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-38134	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-246866	usd
CY2024Q3	ODYY	Unamortized Beneficial Conversion Feature UnamortizedBeneficialConversionFeature	0	usd
CY2023Q3	ODYY	Unamortized Beneficial Conversion Feature UnamortizedBeneficialConversionFeature	-33474	usd
CY2024Q3	us-gaap	Notes Payable Current NotesPayableCurrent	1646533	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	2144660	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11795000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.34
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue	10475000
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.10
CY2024	ODYY	Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod	2800000	shares
CY2024	ODYY	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	0.57
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	250000	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.30
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	750000	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.26
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	18470000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.17
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	198149	usd
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P0Y9M
CY2024	ODYY	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rates EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates	0.21	pure
CY2023	ODYY	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rates EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRates	0.21	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.21	pure
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2024	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	97900	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	485300	usd
CY2024	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-97900	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-485300	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2862500	usd
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2960400	usd
CY2024Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2862500	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2960400	usd
CY2024Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2024Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	28831391	usd
CY2024Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2024Q3	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	1508710	usd
CY2023Q3	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	1193602	usd
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	26028607	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	54956983	shares
CY2024Q3	us-gaap	Litigation Reserve LitigationReserve	20000	usd
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001683168-24-007967-index-headers.html	Edgar Link	pending
0001683168-24-007967-index.html	Edgar Link	pending
0001683168-24-007967.txt	Edgar Link	pending
0001683168-24-007967-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
odyssey_ex1032.htm	Edgar Link	pending
odyssey_ex1060.htm	Edgar Link	pending
odyssey_ex1061.htm	Edgar Link	pending
odyssey_ex1062.htm	Edgar Link	pending
odyssey_ex1063.htm	Edgar Link	pending
odyssey_ex3101.htm	Edgar Link	pending
odyssey_ex3102.htm	Edgar Link	pending
odyssey_ex3201.htm	Edgar Link	pending
odyssey_ex3202.htm	Edgar Link	pending
odyssey_i10k-073124.htm	Edgar Link	pending
odyy-20240731.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
odyy-20240731_def.xml	Edgar Link	unprocessable
odyy-20240731_lab.xml	Edgar Link	unprocessable
odyy-20240731_pre.xml	Edgar Link	unprocessable
odyssey_i10k-073124_htm.xml	Edgar Link	completed
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
odyy-20240731_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ODYY
Odyssey Group of Companies Stock $odyy

2024 Q4 Form 10-K Financial Statement

#000168316824007967 Filed on November 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ODYY Odyssey Group of Companies Stock $odyy

2024 Q4 Form 10-K Financial Statement

#000168316824007967 Filed on November 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ODYY
Odyssey Group of Companies Stock $odyy